<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Freches,D.</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Korf,H.</style></author><author><style face="normal" font="default" size="100%">J.C. Renauld</style></author><author><style face="normal" font="default" size="100%">J. Van Snick</style></author><author><style face="normal" font="default" size="100%">Uyttenhove,C.</style></author><author><style face="normal" font="default" size="100%">K Huygen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice36543</style></title><secondary-title><style face="normal" font="default" size="100%">Clin.Vaccine Immunol.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">an</style></keyword><keyword><style  face="normal" font="default" size="100%">analysi</style></keyword><keyword><style  face="normal" font="default" size="100%">analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">approach</style></keyword><keyword><style  face="normal" font="default" size="100%">approaches</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">Autovaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacillus</style></keyword><keyword><style  face="normal" font="default" size="100%">BCG</style></keyword><keyword><style  face="normal" font="default" size="100%">BCG Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">biosynthesis</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell</style></keyword><keyword><style  face="normal" font="default" size="100%">cells</style></keyword><keyword><style  face="normal" font="default" size="100%">challenge</style></keyword><keyword><style  face="normal" font="default" size="100%">Context</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Deficiency</style></keyword><keyword><style  face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Functional</style></keyword><keyword><style  face="normal" font="default" size="100%">IL-17A</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">immune response</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style  face="normal" font="default" size="100%">immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">INFECTION</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-gamma</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-12</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-17</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-6</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Less</style></keyword><keyword><style  face="normal" font="default" size="100%">LEVEL</style></keyword><keyword><style  face="normal" font="default" size="100%">levels</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">M</style></keyword><keyword><style  face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice,Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">mortality</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium bovis</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Necrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">pathogen</style></keyword><keyword><style  face="normal" font="default" size="100%">prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">production</style></keyword><keyword><style  face="normal" font="default" size="100%">protection</style></keyword><keyword><style  face="normal" font="default" size="100%">protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Pulmonary</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Support</style></keyword><keyword><style  face="normal" font="default" size="100%">response</style></keyword><keyword><style  face="normal" font="default" size="100%">Responses</style></keyword><keyword><style  face="normal" font="default" size="100%">result</style></keyword><keyword><style  face="normal" font="default" size="100%">results</style></keyword><keyword><style  face="normal" font="default" size="100%">Role</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">secretion</style></keyword><keyword><style  face="normal" font="default" size="100%">Spleen</style></keyword><keyword><style  face="normal" font="default" size="100%">System</style></keyword><keyword><style  face="normal" font="default" size="100%">Tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha</style></keyword><keyword><style  face="normal" font="default" size="100%">Up-Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">WIV-ISP</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/1/2011</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">104</style></number><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">95 - 104</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Interleukin-12 (IL-12) and IL-23 (which share a p40 subunit) are pivotal cytokines in the generation of protective Th1/Th17-type immune responses upon infection with the intracellular pathogen Mycobacterium tuberculosis. The role of IL-12 and IL-23 in protection conferred by the tuberculosis vaccine Mycobacterium bovis bacillus Calmette-Guerin (BCG) is, however, less well documented. By using an autovaccine approach, i.e., IL-12p70 cross-linked with ovalbumin and PADRE peptide formulated with the GSK proprietary adjuvant system AS02(V), we could specifically neutralize IL-12 while leaving the IL-23 axis intact. Neutralization of IL-12 before M. tuberculosis challenge rendered C57BL/6 mice highly susceptible, resulting in 30-fold-higher CFU in spleen and lungs and accelerated mortality. In contrast, neutralization of IL-12 in BCG-vaccinated mice prior to M. tuberculosis challenge only marginally affected vaccine-mediated protection. Analysis of cytokine production in spleen and lungs 3 weeks post-TB challenge by enzyme-linked immunosorbent assay and functional and flow cytometric assays showed significantly reduced mycobacterium-specific gamma interferon (IFN-gamma) responses in M. tuberculosis-infected and BCG-vaccinated mice that had been treated with the autovaccine. Purified protein derivative-induced tumor necrosis factor alpha (TNF-alpha), IL-6, and IL-17A levels, however, were highest in lungs from BCG-vaccinated/IL-12-neutralized animals, and even unstimulated lung cells from these mice produced significant levels of the three cytokines. Mycobacterium-specific IL-4 and IL-5 production levels were overall very low, but IL-12 neutralization resulted in increased concanavalin A-triggered polyclonal secretion of these Th2-type cytokines. These results suggest that TNF-alpha, IL-6, and IL-17A may be more important pulmonary effector molecules of BCG-mediated protection than IFN-gamma in a context of IL-12 deficiency</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">38197</style></custom1><section><style face="normal" font="default" size="100%">95</style></section></record></records></xml>